Viridian Therapeutics Reports Q3 Earnings Beat with $24.7 Million in Revenue
Viridian Therapeutics (VRDN) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.81, outperforming estimates by $0.21, while revenue reached $24.7 million, beating projections by approximately $19.98 million despite a 65% year-over-year decline. As of September 30, 2026, the company maintains a strong liquidity position with $955.2 million in cash, cash equivalents, and marketable securities. Management indicated that current cash reserves combined with anticipated commercial revenues from Lumvoa and elegrobart are expected to fund operations through profitability.
Tickers: $VRDN
Topics: cash position earnings beat financial guidance revenue report